Edition:
United States

Aeterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

0.86USD
22 May 2017
Change (% chg)

$-0.00 (-0.01%)
Prev Close
$0.86
Open
$0.86
Day's High
$0.88
Day's Low
$0.85
Volume
113,946
Avg. Vol
342,696
52-wk High
$5.59
52-wk Low
$0.78

AEZS.O

Chart for AEZS.O

About

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $11.87
Shares Outstanding(Mil.): 13.80
Dividend: --
Yield (%): --

Financials

  AEZS.O Industry Sector
P/E (TTM): -- 142.93 17.37
EPS (TTM): -2.34 -- --
ROI: -80.14 2.34 -5.89
ROE: -234.78 0.22 -5.30

BRIEF-Aeterna Zentaris says ZoptEC Phase 3 clinical study of Zoptrex did not achieve primary endpoint

* Aeterna Zentaris announces that ZoptEC Phase 3 clinical study of Zoptrex did not achieve its primary endpoint

May 01 2017

BRIEF-Aeterna Zentaris intends to file NDA with respect to Macrilen in Q3

* Aeterna Zentaris intends to file NDA with respect to Macrilen™ in third quarter of 2017 Source text for Eikon: Further company coverage:

Mar 30 2017

BRIEF-Aeterna Zentaris files for common shares stock shelf offering of up to $50 mln

* Aeterna Zentaris Inc- files for common shares stock shelf offering of up to $50 million - sec filing Source text (http://bit.ly/2mMXM6t) Further company coverage:

Mar 21 2017

BRIEF-Aeterna Zentaris qtrly loss per share $0.71

* Aeterna Zentaris reports fourth quarter and full-year 2016 financial and operating results

Mar 15 2017

BRIEF-Aeterna Zentaris announces EMA pediatric committee agreement

* Aeterna Zentaris announces EMA pediatric committee agreement on the pediatric investigation plan for macrilen(TM)

Mar 07 2017

More From Around the Web

Earnings vs. Estimates